Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Very low-density lipoprotein (VLDL) particle metabolism refers to the physiological processes involved in the synthesis, secretion, transformation, and clearance of VLDL particles in the body. VLDLs are triglyceride-rich lipoproteins produced by the liver that transport endogenous triglycerides and cholesterol from the liver to peripheral tissues for energy utilization or storage. After release into circulation, VLDLs are hydrolyzed by lipoprotein lipase at capillary beds—delivering fatty acids—and are progressively converted into intermediate-density lipoproteins (IDL) and then low-density lipoproteins (LDL), which are more cholesterol-rich particles implicated in cardiovascular risk[1][2]. Abnormalities in this metabolic pathway contribute significantly to dyslipidemia and increased risk for cardiovascular diseases due to plaque formation within arteries when levels become elevated[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Very low-density lipoprotein particle metabolism (VLDL metabolism).